ALS Investment Fund

ALS Investment Fund is a venture capital firm based in Amsterdam, Netherlands, established in 2016. It focuses on investments in biotechnology and life sciences, providing funding and strategic support to biotech companies to advance research, development, and commercialization of innovative therapies and technologies.

Craig H. Boyce

Managing Partner

Felix von Coerper

Managing Partner

9 past transactions

Verge Genomics

Series B in 2021
Verge Genomics is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery for neurodegenerative diseases. The company is founded by experts in machine learning and neuroscience drug development who believe advances in computational genomics can reveal new targets and therapies. Verge Genomics' platform analyzes datasets of any size to identify targets and predict effective drugs, with the aim of delivering treatments that improve patient outcomes while reducing the cost and duration of pharmaceutical development.

Bloom Science

Series A in 2021
Bloom Science is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapeutics for neurological disorders. It employs a gut-brain axis approach through its IrisRx platform to discover and design medicines from gut microbes using synthetic biology, aiming for novel biology and improved safety profiles. The company seeks to translate the therapeutic benefits associated with the ketogenic diet into medicines that treat epilepsy and other central nervous system conditions. Its pipeline encompasses therapies for Dravet syndrome and other rare epilepsies, as well as Amyotrophic Lateral Sclerosis and other neurodegenerative and cognitive disorders. Bloom Science pursues translational research to advance microbe-based therapeutics that address unmet needs in neurology. The company is headquartered in San Diego, California.

Prilenia

Series B in 2021
Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Apic Bio

Series A in 2019
Apic Bio develops gene therapies targeting rare neurological and liver diseases. Its lead product, APB-101, uses an adeno-associated virus vector to silence and augment proteins for treating alpha-1 antitrypsin deficiency.

Verge Genomics

Series A in 2018
Verge Genomics is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery for neurodegenerative diseases. The company is founded by experts in machine learning and neuroscience drug development who believe advances in computational genomics can reveal new targets and therapies. Verge Genomics' platform analyzes datasets of any size to identify targets and predict effective drugs, with the aim of delivering treatments that improve patient outcomes while reducing the cost and duration of pharmaceutical development.

Emulate

Series C in 2018
Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Orphazyme

Venture Round in 2017
Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Amylyx Pharmaceuticals

Series A in 2016
Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.